

Detailed Table of Contents

Chapter 1 Epidemiology	13
Challenges to Studying the Epidemiology of AD.....	13
Prevalence of Childhood AD.....	13
Prevalence of Adult AD.....	14
AD Severity.....	18
Socio-Demographic Risk Factors.....	20
Cost of AD.....	21
Chapter 2 Pathogenesis	27
Skin Barrier Dysfunction.....	28
Genetic Risk Factors for AD.....	28
FLG Loss-of-Function Mutations.....	29
Other Genetic Factors.....	29
Interplay of Epidermal Barrier Dysfunction with Inflammation and Immune Dysregulation	30
Immune Dysregulation in the Pathogenesis of AD	31
IL-4 and IL-13	31
IL-31	34
IL-33	35
OX40/OX40L.....	35
ILC2s.....	36
IL-5	36
TSLP	37
IgE.....	37
Cyclic AMP (cAMP) and Phosphodiesterase 4 (PDE-4).....	38
T _h 17 and T _h 22.....	39
Other Cytokine Pathways	39
JAK-STAT Pathway	40
Infections in Patients with AD	41
Environmental Factors Affecting the Pathogenesis of AD.....	41
Atopic March	42
Chapter 3 Environmental Risk Factors	51
Maternal Exposures During Pregnancy.....	51
Maternal Stress.....	51
Prenatal Antibiotics.....	52
Maternal Exposure to Cigarette Smoke	52
Prenatal Consumption of Alcohol.....	53
Irritants and Pruritogens.....	53
Harmful Effects of Excess Bathing, Hot Water, and Bath Soaps.....	55
Hygiene Hypothesis	56
Climate	57
Temperature.....	57
Humidity.....	57
UV Radiation	59
Latitude	60
Precipitation.....	60
Air Pollutants	60
Indoor Air Pollutants	61
Outdoor Air Pollutants	61
Tobacco Smoke Exposure.....	62
Water Hardness.....	63
Urban vs Rural Living	63
Diet	63
Testing for Food Allergies.....	64
Breast-Feeding.....	65
Probiotics and Prebiotics	65
Prevention of AD Through Early Moisturization	66
Chapter 4 Clinical Presentation	73
Diagnostic Features of AD	73
Hanifin and Rajka Criteria.....	73
Other Diagnostic Criteria	76
Comorbidities.....	77
Biomarkers.....	77
Patient History.....	78
Clinical Presentation	79
Adult-Onset Atopic Dermatitis	84
Hand Eczema.....	85
Nummular Eczema	86
Prurigo Nodules.....	86
Lichenoid Papules	86
Differential Diagnosis.....	87
Seborrheic Dermatitis (SD).....	88
Irritant or Allergic Contact Dermatitis (CD).....	90
Cutaneous T-Cell Lymphoma (CTCL)	91
Psoriasis	91
Dermatitis Herpetiformis (DH)	93
Eczematous Drug Eruptions	94
Hyper-IgE Syndromes (HIES)	94
Scabies	95
Nummular Dermatitis (ND).....	95
Clinical Presentation and Special Considerations for Skin of Color.....	97
Subsets of AD Patients	99
Chapter 5 Diagnosis and Evaluation	105
Diagnostic Criteria	105

Hanifin and Rajka Criteria.....	105	Atopic Comorbidities.....	143
The UK Working Party Criteria	107	Neuropsychiatric Comorbidities.....	149
AAD Criteria	107	Sleep Disturbance	149
New Chinese Criteria for Childhood Atopic		Depression	150
Dermatitis	107	Anxiety	151
Distinguishing AD from Other Disorders	109	Suicidal Ideation	151
Biomarkers	109	Attention Deficit/Hyperactivity Disorder	151
IgE.....	111	Cognitive Dysfunction.....	152
Skin Prick Test (SPT) Positivity.....	111	Other Neuropsychiatric Disorders.....	153
Other Biomarkers	112	Conclusions	153
Disease Severity Scales.....	113	Injuries and Fractures	154
SCORing Atopic Dermatitis (SCORAD)	114	Autoimmune Diseases	155
Objective SCORAD (oSCORAD).....	115	Infections	156
Eczema Area and Severity Index (EASI)	115	Cancer.....	157
Modified EASI (mEASI)	116	Obesity and Cardiovascular Disease	159
Global Assessments	117	Obesity	159
Rajka-Langeland (R-L).....	119	Blood Pressure.....	160
Six Area Six Sign AD (SASSAD)	119	Sleep Disturbance	160
AD Severity Index (ADSI)	120	Physical Activity.....	161
EASI vs SCORAD	120	Cardiovascular Disease	162
Lesional Intensity vs Extent.....	120	Conclusions	163
Patient-Reported Outcomes (PRO) and Quality of Life		Chapter 7 Topical Therapy	171
(QOL) Measures.....	122	Moisturizers	171
Patient-Reported Global Severity of AD.....	123	Recommendations for Nonpharmacologic	
Skin Pain.....	124	Interventions	173
Visual Analogue Scale (VAS)-Pruritus	125	Prescription Emollient Devices (PEDs)	173
Numerical Rating Scale (NRS)-Pruritus	126	Topical Corticosteroids	173
Visual Response Scale (VRS)-Pruritus.....	127	AAD Recommendations for Topical Corticosteroids ..	180
Short Form-36 Health Survey (SF-36)	127	Topical Calcineurin Inhibitors (TCIs)	182
Patient Reported Outcomes Measurement Information		Efficacy	182
System (PROMIS) Global Health (PGH)	128	Safety	183
Short Form-12 Health Survey (SF-12)	129	Dosage and Administration.....	184
Patient-Oriented Eczema Measure (POEM).....	129	AAD Recommendations for TCIs	185
Patient-Oriented SCORAD (PO-SCORAD).....	130	Topical Phosphodiesterase-4 (PDE-4) Inhibitors	185
Patient-Reported Outcomes Measurement Information		Eucrisa (Crisaborole).....	187
System (PROMIS) Itch Questionnaire (PIQ)	131	Management of Steroid-Sparing Agent-Associated	
Dermatology Life Quality Index (DLQI)		Pain.....	192
Children's Dermatology Life Quality Index		Topical Janus Kinase (JAK) Inhibitors	192
(CDLQI)	132	Opzelura (Ruxolitinib)	192
Dermatitis Family Impact (DFI)	133	Bath Treatments	196
Concordance of AD Signs and Symptoms.....	134	Wet Wrap Therapy	198
Concordance of Clinician and Patient Assessments	134	Other Topical Approaches	198
Clinical Outcome Assessments Feasible for		Topical Antihistamines.....	198
Clinical Practice	135	Chapter 8 Phototherapy	205
Chapter 6 Comorbidities	143	Ultraviolet B Radiation (UVB).....	205

Broad-band UVB (BBUVB)	205	Chapter 11 Complementary and Alternative	
Narrow-band UVB (NBUVB)	206	Medicine	277
UVB and Crude Coal Tar (Goeckerman Regimen)	207	CAM and Childhood AD	277
Excimer Laser (308 nm).....	207	Active Natural Ingredients.....	282
Ultraviolet A Radiation (UVA).....	207	Chinese Herbal Medicine (CHM)	282
UVA-1	207	Coconut Oil.....	282
Psoralens and UVA	208	Colloidal Oatmeal.....	283
Combination UVA-UVB	209	Sunflower Oil.....	283
Combination Therapy with Phototherapy	209	Mustard Oil	284
AAD Guidelines on Phototherapy.....	209	Glycerine	284
Pediatric Considerations.....	211	Dietary Supplements.....	284
Limitations of Phototherapy.....	211	Vitamin D	285
Side Effects of Phototherapy.....	214	Probiotics and Prebiotics	285
Home Phototherapy and Tanning Beds.....	214	Bleach Baths.....	286
Conclusions	215	Safety Considerations	286
Chapter 9 Oral Systemic Therapy	219	Conclusions	288
Oral Janus Kinase (JAK) Inhibitors	219	Chapter 12 Coordinated Management	291
Cibinqo (Abrocitinib)	220	Shared Decision Making	292
Rinvoq (Upadacitinib)	226	Multidisciplinary Team Members.....	293
Olumiant (Baricitinib)	228	AD Specialist	293
Systemic Immunosuppressants	231	Mental Health Specialist	294
Azathioprine (AZA)	231	Registered Nurse/Nurse Practitioner	295
Cyclosporine A (CSA).....	234	Dietician	295
Methotrexate (MTX)	237	Sleep Medicine Specialist	296
Mycophenolate Mofetil (MMF).....	240	Patient Education.....	296
Tacrolimus	241	Practical Clinical Strategies.....	298
Systemic Corticosteroids	242	Conclusions	298
Safety	242		
Dosage and Administration.....	243		
Conclusions	244		
Oral Phosphodiesterase-4 (PDE-4) Inhibitors	244		
Apremilast.....	244		
Systemic Antimicrobials	245		
Systemic Antihistamines.....	246		
Other Oral Systemic Therapies Not Recommended			
for AD	248		
Chapter 10 Biologic Therapy	255		
Approved Therapies.....	257		
IL-4/IL-13 Therapies.....	257		
Therapies Not Currently Recommended for			
the Treatment of AD	270		
Interleukin 12/Interleukin 23 Therapies.....	270		
Human Immunoglobulin E (IgE)	270		
Summary	272		
Tumor Necrosis Factor Alpha (TNF- α)	272		